Latest News for: nlrp3

Edit

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

PR Newswire 21 Jan 2026
Through the partnership, the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders ... The NLRP3 ...
Edit

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate

Image Hastings Tribune 20 Jan 2026
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies ... .
Edit

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a ...

Nasdaq Globe Newswire 20 Jan 2026
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies ... .
Edit

BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102, with plans to initiate Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema in mid-2026 (Form 8-K) (Bioage Labs Inc)

Public Technologies 20 Jan 2026
BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102, with plans to initiate Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema in mid-2026 ... Background on BGE-102 and NLRP3.
Edit

Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program

PR Newswire 15 Jan 2026
... of BT-409, the company's novel, brain-selective NOD-, LRR-, and pryin domain-containing protein 3 (NLRP3) inflammasome inhibitor ... Brain-Selective NLRP3 Inhibitor Advancing to First-in-Human Evaluation.
Edit

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, ...

Nasdaq Globe Newswire 12 Jan 2026
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers ... .
Edit

Ace2 safeguards embryonic hematopoietic stem and progenitor cell production by restraining Nlrp3-mediated pyroptosis

PNAS 05 Dec 2025
.
Edit

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Nasdaq Globe Newswire 04 Dec 2025
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing ... .
Edit

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (Form 8-K) (Bioage Labs Inc)

Public Technologies 04 Dec 2025
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor ... BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 ... Background on BGE-102 and NLRP3.
Edit

AHA Scientific Sessions 2025 – Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation: A Novel Therapeutic Approach for Cardiovascular Inflammation (Monte Rosa Therapeutics Inc)

Public Technologies 08 Nov 2025
Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation ... Introduction to NEK7 in NLRP3 Inflammasome Activation ... NLRP3 ... Activation of the NLRP3. NLRP3 NEK7. NLRP3 ... NLRP3.
  • 1

Article Search

tools
×
×
×
×